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Magnesium sulfate (MgSO4) has been considered as an adjunct therapy for severe and life-threatening asthma exacerbation. 
The literature search was performed using MEDLINE, EMBASE, Cochrane Library and Google Scholar to summarize the current state 
of knowledge regarding magnesium therapy in acute exacerbation of adult asthma. A total of 16 trials and 4 meta-analyses were 
identified. As results, intravenous MgSO4 was beneficial in severe exacerbation, but evidence for nebulized magnesium was insufficient. 
However, larger trials are required to draw confirmative conclusions on the efficacy. Regarding the safety concern, the risk of major 
toxicity appears to be very low at usual doses described in the literature. Additionally, results from 4 surveys were examined on the 
gaps between knowledge and practice, and on the barrier to the use of MgSO4 at emergency departments. This literature review 
summarized the up-to-date evidence on the issues regarding the use of MgSO4 for acute asthma. We expect more studies to be 
conducted for evidence making in the Asian-Pacific regions.
Key words: Asthma; Magnesium sulfate; Emergency treatment; Review 
INTRODUCTION
Magnesium sulfate (MgSO4) has been considered as an adjunct 
therapy for severe and life-threatening asthma exacerbation. 
Theoretically, magnesium can induce bronchial smooth muscle 
relaxation in a dose-dependent manner [1] by inhibiting calcium 
influx into the cytosol [2], histamine release from mast cells [3], 
or acetylcholine release from cholinergic nerve endings [4]. It 
also may increase the bronchodilator effect of β2-agonist by 
increasing the receptor affinity [5]. Historically, in the literature, 
the first description on the clinical use of magnesium for asthma 
was reported in 1936 [6]. In 1987, Okayama et al. [7] reported 
rapid bronchodilating effects of intravenous (IV) MgSO4 infusion 
in 10 asthma patients. In 1989, its effect was also reported for 
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prevention of endotracheal intubation and mechanical ventilation 
in an elderly asthma patient with severe exacerbation [8]. 
The first randomized controlled trial (RCT) was conducted in 
1989 by Skobeloff et al. [9] to investigate its efficacy. Since then, 
it has been examined by several RCTs and meta-analyses. At the 
same time, the use of nebulized MgSO4 has also gained scientific 
interests. Current guidelines [10-12] suggest the use of IV MgSO4 
as an adjunct therapy to improve pulmonary functions and 
reduce hospital admission in certain patients with severe and life-
threatening acute exacerbations unresponsive to initial treatments, 
whereas the evidence has been weaker for nebulized magnesium. 
In this review, we aimed to summarize the current state of 
knowledge regarding the use of MgSO4 in acute exacerbation of 
adult asthmatics.
Key question 
Population: adult asthma patients with acute exacerbation
Intervention: MgSO4 (intravenous or nebulized form)
Control: placebo
Outcome: clinical efficacy 
Search strategy
The literature search was performed during the period 
September 2011 until December 2011. Articles were searched 
from MEDLINE, EMBASE, the Cochrane Library and Google Scholar. 
Search terms included the terms for asthma, exacerbation and 
magnesium. Additionally, manual searching the references for 
relevant articles was also performed on respiratory or emergency 
medicine journals. The search for unpublished data was not 
conducted. The search was limited to the last 25 years (1986 to 
2011).
First, authors scanned titles, abstracts, and selected relevant 
articles for retrieval of full-text. Through a full-text review, final 
selection was made: RCTs were included if they were conducted 
on adult acute asthmatics and compared its efficacy with placebo. 
The quality of included RCTs were determined by the five point 
Jadad score [13]. Meta-analyses were included if they included 
the issues relevant to our key question. Suspected duplicates 
were excluded. Finally, 10 RCTs for IV MgSO4, 6 RCTs for nebulized 
MgSO4, and 4 meta-analyses were included. All the identified 
articles were originally written in English, although attempts 
were made to find out non-English sources including Korean and 
Japanese.
Data extraction
The following data were extracted: study design, study 
population (patients, or number of pooled trials), interventions, 
control, co-treatments, and outcomes of interest. 
Additional search
Articles were searched again from the same electronic databases 
to retrieve information on the practice status at emergency 
departments regarding the use of MgSO4 in acute asthma patients. 
This search was not limited to adult population, because studies 
were scarce. Finally, 4 original articles were selected. 
Included studies
Included RCTs were summarized in Tables 1 and 2. Overall 
quality of RCTs was high, having a Jadad score of 4 or 5 in 11/16 
trials. The majority (13/16) of the studies were double-blinded, 
while two trials [14, 15] for IV and one trial [16] for nebulized 
MgSO4 were single-blinded. However, heterogeneity was identified 
for the included trials. For RCTs on IV form, there were variations 
in the severity of attack, definition of severity, treatment dose (2 g 
bolus in 6/10 trials), co-treatments (IV theophylline/aminophylline 
in 5/10 trials, and nebulized ipratropium in 2/10 trials), and timing 
to measure outcomes. As for nebulized form, there was notable 
heterogeneity in the treatment dose of nebulized MgSO4. 
The included meta-analyses were described in Table 3. A meta-
analysis by Mohammed et al. [17] was the most up-to-date and 
comprehensive one including most of published RCTs and also 
unpublished data such as conference abstracts. Three recently 
published RCTs [15, 18, 19], not included in the meta-analyses, had 
distinct points from previous trials in that the recent trials used 
nebulized ipratropium as one of the routine treatments.
Efficacy of intravenous MgSO4
There have been 3 meta-analyses and 2 recent RCTs. The results 
from the Cochrane review by Rowe et al. [20] stated that IV MgSO4 
as adjunct to standard treatment was beneficial in severe acute 
asthma patients, both in terms of pulmonary functions and 
hospital admission rate. The results by Rodrigo et al. [21] were 
not concordant, but the number of pooled studies and patients 
were smaller than the Cochrane review. The recent reviews by 
Mohammed et al. [17] found that the efficacy was only marginal 
on pulmonary function (standardized mean difference (SMD) 0.25, 
95% confidence interval (CI) –0.01 to 0.51), and not significant 
on hospital admission (relative risk (RR) 0.87, 95% CI 0.70 to 1.08). apallergy.org
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Table 1. Summary of randomized placebo-controlled trials for efficacy of intravenous MgSO4 in acute exacerbation of adult asthmatics
Refer-
ence Country Study population 
(age range) Intervention  Routine 
co-treatment
Measures of 
outcome Results Jadad 
score
[15]  India
60 severe patients 
(18-60 yr)
2 g MgSO4
Nebulized: salbutamol, 
ipratropium
Systemic: hydrocortisone 
100 mg
FEV1% predicted, 
and discharge rate 
at 120 min
Improvement in 
pulmonary function 
and decrease in 
hospital admission
3
[19]  UK
129 moderate to severe 
patients 
(≥ 16 yr)
1.2 g MgSO4
Nebulized: salbutamol, 
ipratropium
Systemic: hydrocortisone 
200 mg
PEF% predicted, 
and admission rate
 at 60 min
No benefit even in 
severe patients
5
[42]  USA
248 severe patients 
(18-60 yr)
2 g MgSO4
Nebulized: albuterol
Systemic: methylpredniso-
lone 125 mg
FEV1% predicted,
and admission rate 
at 240 min
Improvement in 
pulmonary function 
(in very severe 
patients with FEV1 
< 20% predicted), 
but no benefit in 
admission rate
5
[43]  Iran
81 patients with PEFR < 
200 L/min, non-respond-
ing to routine therapy 
(12-85 yr)
25 mg/kg MgSO4
Nebulized: salbutamol
Systemic: corticosteroids, 
aminophylline
PEFR% predicted at 180 
min
Improvement in 
pulmonary function
3
[44]  USA
42 moderate to severe  
patients (18-55 yr)
2 g MgSO4
Nebulized: albuterol
Systemic: methylpredniso-
lone 125 mg
PEFR% predicted, 
Borg dyspnea scale,
and admission rate
No benefit 5
[45]  Thailand
33 patients with 
Fischl’s severity 
score > 4 (15-65 yr)
2 g MgSO4
Nebulized: salbutamol
Systemic: dexamethasone 
5 mg
Admission rate, 
and severity score 
at 240 min
No benefit 5
[46]  USA
135 patients with FEV1 
< 75% predicted 
(18-65 yr)
2 g MgSO4
Nebulized: albuterol
Systemic: methylpredniso-
lone 125 mg, theophylline
FEV1% predicted, 
and admission rate 
at 120 min
Improvement in 
pulmonary function, 
and decrease in 
admission rate, but 
only among severe 
patients with FEV1 
< 25% predicted
5
[26]  USA
48 patients with PEFR 
< 200L/min, unresponsive 
to two albuterol 
treatments (18-60 yr)
2 g MgSO4 bolus, 
followed by infu-
sion of 2 g/h over 
4 h
Nebulized: albuterol
Systemic: methylpredniso-
lone 125 mg, aminophylline
PEFR% predicted, 
FEV1% predicted 
at 260 min
No benefit 4
[14]  USA
120 patients unresponsive 
to a single albuterol 
treatment (18-65 yr)
2 g MgSO4
Nebulized: albuterol
Systemic: methylpred-
nisolone 125 mg, theophyl-
line, injectable β-agonist, 
epinephrine
Admission rate, 
ED treatment time, 
and PEFR% predicted
No benefit 1
[9]  USA
38 moderate to severe 
patients unresponsive to 
beta-agonist treatment 
(18-70 yr)
1.2 g MgSO4
Nebulized: metaproterenol 
or albuterol
Systemic: methylpredniso-
lone 125 mg, and theophyl-
line
PEFR% predicted 
at 45 min, and 
admission rate
Improvement in 
pulmonary function, 
and decrease in 
admission rate
5
MgSO4, magnesium sulfate; FEV1, forced expiratory volume in 1 sec; PEFR, peak expiratory flow rate; ED, emergency department. apallergy.org
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However, their analyses were not confined to severe exacerbations. 
Notably, two recent RCTs used nebulized ipratropium bromide 
as their standard treatments. The trials by Bradshaw et al. [19] did 
not show additional benefit of 1.2 g IV MgSO4 even in subgroups 
of life-threatening exacerbation. However, the trials by Singh et 
al. [15] showed its positive effect on forced expiratory volume in 
1 second (FEV1) % predicted (vs. placebo; mean difference 6.07, 
95% CI 1.87 to 10.62), but had limitations in smaller number of 
participants and single-blinded design. 
Nebulized ipratropium is currently recommended as an 
additional bronchodilator for moderate exacerbation by 
guidelines, and is being widely used in practice. Therefore, the 
efficacy of IV MgSO4 needs to be examined further in the context 
of current treatment guidelines. Nevertheless, the use of MgSO4 
should not be hesitated in patients with severe life-threatening 
asthma exacerbation unresponsive to standard treatments, 
because its toxicity was minimal. 
Efficacy of nebulized MgSO4
There have been 2 meta-analyses and 1 recent RCT. The 
Cochrane review conducted by Blitz et al. [22] showed that 
nebulized MgSO4 improved pulmonary functions (SMD 0.55, 95% 
CI 0.12 to 0.98) in severe subgroups (FEV1 or peak expiratory flow 
<50% predicted). However, the results were based on only 87 
adult asthmatics from 2 trials. The recent reviews by Mohammed 
et al. [17] examined more trials and found that nebulized MgSO4 
had marginal benefits on pulmonary functions (SMD 0.17, 95% 
CI −0.02 to 0.36) and on hospital admission rate (RR 0.68, 95% CI 
0.46 to 1.02). Considering the heterogeneity in treatment doses, 
severity of patients and small numbers of pooled studies, they 
concluded that evidence is insufficient to draw conclusions. 
In a recent trial (n = 60) by Gallegos-Solórzano et al. [18], 
when added to standard treatments of nebulized albuterol 
and ipratropium, nebulized MgSO4 therapy improved post-
bronchodilator lung functions and oxygen saturation, and reduced 
admission rates at 90 min. However, the largest trial (n = 100) 
by Aggarwal et al. [23] failed to show any benefit of additional 
MgSO4 therapy. Taken together, the use of nebulized MgSO4 might 
be beneficial in treating severe exacerbation, but large trials are 
required for more definite conclusion. 
Table 2. Summary of randomized placebo-controlled trials for efficacy of nebulized MgSO4 in acute exacerbation of adult asthmatics
Refer-
ence Country Study population 
(age range) Intervention  Routine 
co-treatment
Measures of 
outcome Results Jadad 
score
[18]  Mexico
60 severe patients 
(> 18 yr)
333 mg MgSO4 
every 20 min 
(total 3 doses)
Nebulized: albuterol, 
ipratropium
Systemic: 
methylprednisolone
FEV1% predicted, 
oxygen saturation, 
admission at 90 min
Improvement in pulmonary 
function and oxygen satura-
tion, and decrease 
in admission rate
4
[23]  India
100 severe to life-
threatening patients 
(13-60 yr)
500 mg MgSO4 
every 20 min 
(total 3 doses)
Nebulized: salbutamol
Systemic: 
hydrocortisone
PEFR% predicted 
at 120 min
No benefit 5
[16]  Turkey
26 moderate to 
severe patients 
(18-60 yr)
145 mg MgSO4 
every 20 min 
(3 doses for 1st h), 
and 4 additional 
hourly doses
Nebulized: salbutamol
Systemic: 
methylprednisolone 
1 mg/kg
PEFR% predicted at 
240 min, and
duration of 
achieving target-
PEFR 70% predicted
No benefit 2
[47] 
New 
Zealand
52 severe patients, 
FEV1 < 50% 
predicted after 
salbutamol treatment 
(16-65 yr)
151 mg MgSO4 
every 20 min 
(total 3 doses)
Nebulized: salbutamol
Systemic: hydrocortisone 
100 mg
FEV1% predicted 
at 90 min
Improvement in 
pulmonary function
Enhanced improvement 
in life-threatening asthma 
(baseline FEV1 <30%)
5
[48]  USA
74 mild to 
moderate patients 
(18-65 yr)
384 mg MgSO4 
every 20 min 
(total 3 doses)
Nebulized: albuterol
Systemic: hydrocortisone 
2 mg/kg every 6 hours
FEV1% predicted 
at 125 min
No benefit 5
[49]  Argentina
35 patients 
(> 18 yr)
225 mg MgSO4 
(1 dose)
Nebulized: salbutamol
PEFR% predicted 
at 20 min
Improvement in 
pulmonary function
3
MgSO4, magnesium sulfate; FEV1, forced expiratory volume in 1 sec; PEFR, peak expiratory flow rate.apallergy.org
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Formulation and optimal dose 
The dose of IV magnesium was 2 g as a bolus in most trials 
showing its effectiveness. The Cochrane review examined the 
safety of 2 g magnesium to find out its minimal risk of significant 
adverse reaction [20]. A RCT [6] using 2 g reported no major 
toxicities but only minor ones in 58% of patients (sensation of 
flushing, mild fatigue and burning sense at IV site). In a trial using 
1.2 g bolus [13], the rate of minor side effect was 8% (headache, 
flushing and dizziness).
For more than two decades, magnesium has been used as a 
tocolytic agent for preterm labor, at higher doses (such as a 6 
g IV load over 20 min and followed by a continuous infusion of 
2 to 4 g/h [24]). Major toxicity occurred at serum magnesium 
level of 9 mg/dL or higher, such as loss of reflexes, blurred vision, 
lethargy, muscle weakness or pulmonary edema [24]. However, 
magnesium is usually excreted in urine, and administration of 2 g 
in a bolus increases the concentration just from 2.2 to 2.8 mg/dL 
30 min after the infusion [25]. Therefore, it can be concluded that 
the usual dose of 2 g for acute asthma has a minimal risk of major 
toxicity in patients with normal renal function, as suggested by 
Table 3. Summary of systematic reviews and meta-analyses: randomized placebo-controlled trials for the efficacy of MgSO4 as an adjunct 
therapy for acute asthma in adults
Form of
MgSO4
Reference Number of 
pooled trials
Outcomes of 
interest Results Author conclusions
IV [17] 
9 trials 
(826 adult patients)
Pulmonary function
Admission rate
Pulmonary function: SMD 0.25 
(−0.01 to 0.51)
Admission rate: RR 0.87 
(0.70 to 1.08)
Evidence is weak for IV MgSO4 to 
improve respiratory functions and 
hospital admissions in adults. 
Nebulized [17] 
7 trials 
(430 adult patients)
Pulmonary function
Admission rate
Pulmonary function: SMD 0.17 
(−0.05 to 0.39)
Admission rate: RR 0.68 
(0.46 to 1.02)
Evidence is weak for nebulized MgSO4
to improve respiratory functions and 
hospital admissions.
Nebulized [22] 
3 trials 
(161 adult patients) 
Pulmonary function: 
20 min, 60 min
Admission to hospital
Pulmonary function:
SMD 0.18 (−0.13 to 0.50)
For severe (FEV1 or PEFR <50% 
predicted): SMD 0.55
(0.12 to 0.98)
Admission:
RR 0.62 (0.38 to 1.02)
For severe (FEV1 or PEFR <50% 
predicted): the same
Nebulized MgSO4 should be 
considered 
as an adjunct therapy to 
beta2-agoinsts 
in asthma exacerbations, particularly 
in more severe exacerbations. 
IV [20] 
7 trials (total of 665 
patients), including 2 
pediatric trials 
(78 patients)
Admission to hospital
Pulmonary function
Admission: OR 0.31 
(0.09 to 1.02)
For severe: OR 0.10 (0.04 to 0.27)
Pulmonary function:
PEFR WMD 29.4 L/min 
(−3.4 to 62)
For severe: FEV1% predicted WMD 
9.8 (3.8 to 15.8)
PEFR WMD 52.3 L/min 
(27.0 to 77.5) 
MgSO4 appears to be beneficial in 
patients who present with severe 
acute asthma.
IV [21] 
5 trials 
(374 adult patients)
Pulmonary function
Admission rate
Pulmonary function:
Effect size 0.02 (−0.20 to 0.24)
Admission: OR 0.68 (0.41 to 1.15)
The addition of MgSO4 in patients with 
moderate to severe asthma exacerba-
tions does not alter treatment out-
comes.
MgSO4, magnesium sulfate; IV, intravenous; SMD, standardized mean difference; RR, relative risk; FEV1, forced expiratory volume in 1 sec; PEFR, peak expira-
tory flow rate; OR, odds ratio; WMD, weighted mean difference.apallergy.org
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the meta-analyses [20]. The possibility exists that higher dose of 
IV magnesium is more effective, but still no published report has 
directly examined the benefit from high dose bolus therapy such 
as 4 g. One trial evaluated the role of continuous MgSO4 infusion, 
but failed to find its additional benefit [26]. 
Hypermagnesemia can be managed by prompt cessation of 
magnesium infusion in patients with normal renal functions. 
However, hemodialysis and IV calcium gluconate may be required 
in high risk patients with renal dysfunctions, bowel obstruction 
[27], or in elderly patients taking magnesium-containing cathartics 
[28].
In cases of nebulized magnesium, optimal dosing may be more 
intricate. MgSO4 is administered by a nebulizer, as a vehicle for 
β2-agonist (and also as in combination). However, hypertonic or 
hypotonic nebulized solution can cause bronchoconstriction by 
itself in asthmatics [29, 30]. Therefore, larger dose of magnesium 
may not be feasible due to practical reasons such as nebulizer 
volume, or the need for specific concentration of MgSO4 to make 
an isotonic solution. For example, in a trial by Aggarwal et al. [23], 
they made magnesium-containing solutions (10 mL, 295 mosmol/
kg) as following: 1 mL of salbutamol solution, 1 mL of MgSO4 (from 
IV preparation at concentration of 500 mg/mL), plus 8 mL distilled 
water. 
At the moment, there is no available evidence to advocate the 
use of higher dose of nebulized magnesium for yielding a better 
efficacy. Moreover, no dose-response relationships (from 0 to 360 
mg MgSO4) have been reported [31]. Nebulized MgSO4 therapy 
can be considered as safe, because no serious side effects were 
reported [22].  
Monitoring serum magnesium levels
As pre-existing magnesium deficit could be associated 
with risk of asthma exacerbation [32-35], one might think 
that serum magnesium level could be measured for adequate 
supplementation or prediction of treatment response. However, 
it is predominantly an intracellular ion, and its serum level does 
not reflect intracellular concentrations or total body stores. 
Its intracellular concentration was found to be lower in acute 
exacerbation and returned to normal when controlled, while 
plasma level remained unchanged [36]. Therefore, serum level 
does not represent the degree of cellular deficit, and it would not 
be useful to monitor serum magnesium level for enhancing the 
efficacy of MgSO4 therapy.
Gap and barrier to the use of MgSO4 
Current guidelines [10-12] suggest the use of IV MgSO4 as an 
adjunct to standard treatment in acute severe exacerbations (Table 
4). Four observational studies evaluated the implementation of 
treatment guidelines with regard to the use of MgSO4 (Table 5). 
They were conducted in North America, UK, Australia and New 
Zealand.
In North America, a large-scale study [37] was conducted on 
patient cohorts and emergency physicians to investigate the use 
of IV MgSO4. Among 9745 emergency department (ED) patients, 
only 2.5% received IV MgSO4. In logistic regression analyses, its 
use was associated with older age, previous intubation history, 
higher respiratory rate, lower initial pulmonary functions, higher 
number of β2-agonists use, and use of systemic corticosteroids. For 
physicians at ED, 92% had MgSO4 available and 64% had recently 
used it. They tipped severity (96%) and poor response to initial β2-
agonists (87%) as main factors prompting the use of MgSO4.
In an online survey of two national pediatric ED physicians 
in North America [38], 88% of physicians knew the efficacy of 
IV MgSO4, but 37.7% of physicians did not use IV MgSO4 in the 
management of severe acute asthma. Main barriers to the use 
were lack of needs (31%) and concerns of side effects (24%).
In a postal survey undertaken for all adult EDs within the UK 
[39], IV MgSO4 was currently being used in 93% of EDs, and more 
than 80% of severe or life-threatening asthma patients received 
the therapy. The reasons for using the agent were to improve 
breathlessness (70%) or reduce admissions (51%). Nebulized 
MgSO4 was being rarely used (1%), and the main reason was 
insufficient evidence (51%). 
In a study conducted in Australia and New Zealand [40], they 
compared the gaps between clinical practice guideline (CPG) 
recommendations and self-reported physician management 
from 11 pediatric EDs. The gap between CPG and practice was 
particularly wide for severe to critical asthma. For IV MgSO4, it has 
been utilized in the practice for 7.7% of severe asthma and 55.1% 
of critical asthma (in CPG: 18.2% and 45.5%, respectively). The 
limitation of this study was that discrepancy existed between New 
Zealand and Australian guidelines on the recommendation of the 
use of magnesium. 
Taken together, overall degree of knowledge among ED 
physicians appears to be high among examined countries. 
However, the significant gaps were found between the knowledge 
and the practice patterns except UK.apallergy.org
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Studies from the Asia-Pacific regions
There have been four RCTs on the efficacy of MgSO4 from the 
Asia-Pacific regions (two from India, and Iran and Thailand for 
each). Their results were conflicting, but did not have notable 
differences from Western studies in their study designs or 
outcome measures. No information was available to determine 
ethnic differences on the efficacy of MgSO4 therapy. However, IV 
aminophylline has been used at EDs more widely in Korea and 
Japan than Western countries due to belief that the agent is not 
very toxic for the Northeast Asian people such as the Korean or the 
Japanese. In a Japanese prospective safety survey conducted by 
Ohta et al. [41], IV aminophylline treatment was found to be highly 
safe among the Japanese adult patients (age: 15-65 years) when 
administered in accordance with the guidelines and instructions. 
Its toxicity occurred in 0.29% of 682 patients, and all of them were 
mild. Thus we guess that the needs for an adjunct magnesium 
therapy might be lower in the Northeast Asia region than Western 
countries. 
We have no more information on the current status of 
knowledge and practice regarding the use of MgSO4 for acute 
asthma in this region. 
CONCLUSION
IV MgSO4 as an adjunct to standard treatment may be beneficial 
in the treatment of adult patients with severe or life-threatening 
exacerbation. The role of nebulized MgSO4 is less evident due to 
Table 4. Current guideline recommendations regarding the use of MgSO4 for acute exacerbation of adult asthma
Guideline [Reference]  Recommendation
GINA [10] 
Intravenous magnesium sulphate (usually given as a single 2 g infusion over 20 min) is not recommended for routine use 
in asthma exacerbations, but can help reduce hospital admission rates in certain patients, including adults with FEV1 <25-
30% predicted at presentation, adults and children whose FEV1 fails to respond to initial treatment, and children whose 
FEV1 fails to improve above 60% predicted after 1 hour of care (Evidence A). 
Nebulized salbutamol administered in isotonic magnesium sulfate provides greater benefit than if it is delivered in normal 
saline (Evidence A).
NAEPP [11] 
Consider intravenous MgSO4 in patients who have life-threatening exacerbations and in those whose exacerbations r
emain in the severe category after 1 hour of intensive conventional therapy (Evidence B). 
A recent meta-analysis of six trials suggests that the use of nebulized MgSO4 in combination with SABAs may result in 
further improvements in pulmonary function, but further research is needed.
BTS/SIGN [12] 
Consider giving a single dose of IV magnesium sulphate for patients with:
•acute severe asthma who have not had a good initial response to inhaled bronchodilator therapy
•life threatening or near fatal asthma (Grade of recommendation B).
National Asthma Council 
Australia [50] 
Magnesium sulphate (via nebuliser or IV, as available) can be added to improve airflow, although the evidence to support 
this is not strong. Suggested doses are 1.2-2 g of MgSO4 IV over 20 min or 2.5 mL isotonic MgSO4 (250 mmol/L) by nebu-
liser.
India [51] 
In patients with acute severe asthma who have not had a good initial response, administration of a single dose of 
intravenous magnesium sulfate (2 g over 20 min) improves pulmonary function when used as an adjunct to standard 
therapy. The treatment should however be used with great caution under proper monitoring.
Japanese Society of 
Allergology [52] 
No statement
Korean Academy of Asthma, 
Allergy and Clinical 
Immunology [53] 
Intravenous MgSO4 (as 2 g a single bolus over 20 min) is not routinely recommended for acute asthma exacerbation. 
However, it can be beneficial in patients with FEV1 <25-30% predicted, or FEV1 <60% predicted after 1 hour of initial emer-
gency treatment (Evidence A). 
Bronchodilating effects may be further enhanced by inhalation of salbutamol and MgSO4 together (Evidence A). 
(translated into English by authors)
MgSO4, magnesium sulfate; GINA, Global Initiative for Asthma; NAEPP, National Asthma Education and Prevention Program; BTS, British Thoracic Society; 
SIGN, Scottish Intercollegiate Guidelines Network; FEV1, forced expiratory volume in 1 sec; SABA, short-acting beta-agonist.apallergy.org
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insufficient evidence. The use of MgSO4 has excellent safety profile 
if appropriately administered. Studies are needed to investigate 
its role and to identify the gaps between guidelines and practice 
patterns in the Asia-Pacific region.
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